Download PDF
Thromb Haemost 2008; 100(02): 179-180
DOI: 10.1160/TH08-07-0437
Editorial Focus
Schattauer GmbH

Do we need thrombin generation assays for monitoring anticoagulation?

Carl-Erik Dempfle
1   I. Department of Medicine, University Hospital of Mannheim, Mannheim, Germany
,
Martin Borggrefe
1   I. Department of Medicine, University Hospital of Mannheim, Mannheim, Germany
› Author Affiliations
Further Information

Publication History

Received 08 July 2008

Accepted 08 July 2008

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
    CrossrefPubMedGoogle Scholar
  • 2 Makris M, Hough RE, Kitchen S. Poor reversal of low molecular weight heparin by protamine. Br J Haematol 2000; 108: 884-885.
    CrossrefPubMedGoogle Scholar
  • 3 Gatt A, van Veen JJ, Woolley AM. et al. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost 2008; 100: 350-355.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Wolzt M, Weltermann A, Nieszpaur-Los M. et al. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man. Thromb Haemost 1995; 73: 439-443.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Holst J, Lindblad B, Bergqvist D. et al. Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers. Blood Coagul Fibrinolysis 1994; 05: 795-803.
    CrossrefPubMedGoogle Scholar
  • 6 Crowther M, Lim W. Low molecular weight heparin and bleeding in patients with chronic renal failure. Curr Opin Pulm Med 2007; 13: 409-413.
    CrossrefPubMedGoogle Scholar
  • 7 Brophy DF, Martin EJ, Gehr TW. et al. Thrombin generation time is a novel parameter for monitoring en-oxaparin therapy in patients with end-stage renal disease. J Thromb Haemost 2006; 04: 372-376.
    CrossrefPubMedGoogle Scholar
  • 8 Bijsterveld NR, Moons AH, Boekholdt SM. et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-2554.
    CrossrefPubMedGoogle Scholar
  • 9 Lisman T, Bijsterveld NR, Adelmeijer J. et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondapari-nux. J Thromb Haemost 2003; 01: 2368-2373.
    CrossrefPubMedGoogle Scholar
  • 10 Young G, Yonekawa KE, Nakagawa PA. et al. Rec ombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fonda-parinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis 2007; 18: 547-553.
    CrossrefPubMedGoogle Scholar
  • 11 Brophy DF, Carr Jr. ME, Martin EJ. et al. The phar-macokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies. J Clin Pharmacol 2006; 46: 887-894.
    CrossrefPubMedGoogle Scholar
  • 12 Gerotziafas GT, Depasse F, Chakroun T. et al. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma. Blood Coagul Fibrinolysis 2004; 15: 149-156.
    CrossrefPubMedGoogle Scholar
  • 13 Gerotziafas GT, Petropoulou AD, Verdy E. et al. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007; 05: 955-962.
    CrossrefPubMedGoogle Scholar
  • 14 Gerotziafas GT, Elalamy I, Depasse F. et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007; 05: 886-888.
    CrossrefPubMedGoogle Scholar